Trials / Withdrawn
WithdrawnNCT01652937
BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BIIB057 in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Biogen · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II study designed to evaluate the safety and efficacy of BIIB057 in Subjects with Rheumatoid Arthritis who have experienced an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB057 | Oral |
| DRUG | Placebo | Oral |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2014-02-01
- Completion
- 2014-03-01
- First posted
- 2012-07-30
- Last updated
- 2013-09-16
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01652937. Inclusion in this directory is not an endorsement.